6
Oct
2026
Canexis Pharma AG
About Canexis Pharma AG
Certifications
-
GMP -
ISO
Categories
Meet us at
-
CPHI Milan 2026
Fiera Milano, Italy
6 Oct 2026 - 8 Oct 2026stand 2D98
-
Country/Region:Switzerland
-
Founded:2020
-
On CPHI since:2025
-
Certificates:3
-
Employees:1 - 24
Company types
Primary activities
Contact info
-
-
-
Hauptstrasse 25, 8255, Schlattingen, Switzerland
Products from Canexis Pharma AG (9)
-
Product Cannabidiol Ph. Eur.
Cannabidiol Ph. Eur. is a phyto-derived, highly purified cannabinoid active pharmaceutical ingredient isolated from Cannabis sativa L. and manufactured in accordance with the European Pharmacopoeia monograph for cannabidiol. After GMP release testing of the starting material, the product is purified and cr... -
Product Dronabinol
Dronabinol is a phyto-derived Δ9-tetrahydrocannabinol active pharmaceutical ingredient isolated from Cannabis sativa L. Following GMP release testing of the starting material, it is purified through validated process steps to obtain a highly concentrated resinous product with an assay of at least 95.0 % Δ9... -
Product THCA (Tetrahydrocannabinolic acid)
THCA (Δ9-tetrahydrocannabinolic acid) is the native, non-decarboxylated acid form of Δ9-THC found in Cannabis sativa L. Canexis isolates and purifies THCA from GMP-released cannabis starting material through validated extraction and purification steps at its EU-GMP site in Schlattingen, Switzerland, in the... -
Product Cannabis Extract (THC)
Cannabis Extract (THC) is derived from cannabis flowers in accordance with the European Pharmacopoeia monograph for cannabis flower. After receipt from qualified suppliers, the starting material is released under GMP and processed through a validated extraction route followed by two refinement steps that d... -
Product Cannabis Extract (CBD)
Cannabis Extract (CBD) is derived from cannabis flowers in accordance with the European Pharmacopoeia. After GMP release testing of the starting material, it is processed through validated extraction, solvent-removal and decarboxylation steps at our EU-GMP site in Schlattingen, Switzerland. The result is a... -
Product Cannabis Distillate (THC)
Cannabis Distillate (THC) is produced from cannabis-derived extract through an additional validated refining step using two-stage short-path distillation. The process removes most terpenes and pigments and yields a transparent orange-golden distillate with a THC-dominant profile and up to 95 % cannabinoids... -
Product Cannabis Distillate (CBD)
Cannabis Distillate (CBD) is produced through validated refinement of cannabis extract using short-path distillation. The process reduces terpenes and pigments and delivers a transparent yellow-golden to crystalline distillate with a CBD-dominant profile and up to 95 % cannabinoids. Depending on storage te... -
Product Standardized Cannabis Extract Type I
Standardized Cannabis Extract Type I is prepared from validated Cannabis Extract (THC) and Cannabis Extract (CBD) and adjusted with medium-chain triglycerides (MCT) to the required cannabinoid profile. After GMP release testing of each starting material, the product is blended and controlled to deliver a t... -
Product Standardized Cannabis Extract Type II
Standardized Cannabis Extract Type II is prepared from validated Cannabis Distillate (THC) and Cannabis Distillate (CBD) and adjusted with medium-chain triglycerides (MCT) to the required cannabinoid profile. The use of refined distillates provides a cleaner and more defined matrix and supports reproducibl...
Canexis Pharma AG Resources (1)
-
Brochure Canexis Pharma – Cannabis APIs: portfolio flyer (PDF)
Two-page overview of the Swiss EU-GMP cannabinoid portfolio: Cannabidiol Ph. Eur., Dronabinol, cannabis extracts and distillates, standardized extracts – with key specifications and pack sizes. Full catalogue on request at www.canexis.com. Professional use only.